{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.8","upperLimit":"91.1","value":"75.0"},{"groupId":"OG001","lowerLimit":"46.0","upperLimit":"84.6","value":"68.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"First Line Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.6","upperLimit":"79.7","value":"61.1"},{"groupId":"OG001","lowerLimit":"21.5","upperLimit":"78.5","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Second Line Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"ORR: percentage of participants who achieved BOR of confirmed CR/PR per RECIST v1.1 as assessed by response reported by investigator on eCRF. CR: complete disappearance of all target lesions (with exception of nodal disease) and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis \\<10 mm. PR: \\>=30% decrease under baseline of sum of diameters of all target measurable lesions. PD: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm for target disease or unequivocal progression of pre-existing lesions for non-target disease or any new lesion. Percentage of participants with ORR for first line (no prior treatment) and second line (participant received prior treatment viz. advanced/metastatic or locoregional disease or maintenance or if neoadjuvant/adjuvant with a disease recurrence occurred during or within 6 months of last therapy dose) is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received encorafenib 300 milligrams (mg) once daily (QD) orally (received after Cycle 1 Day 3) and cetuximab 500 mg per square meters (mg/m\\^2) intravenous (IV) infusion for 120 minutes once every 2 weeks (Q2W) along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 1 [EC + FOLFIRI]"},{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG001","title":"SLI: Cohort 2 [EC + mFOLFOX6]"}],"paramType":"NUMBER","populationDescription":"The FAS for SLI included all participants who were randomized in the SLI portion of the study. Here, \"Number Analyzed\" signifies participants evaluable for specified rows. All participants under \"Overall Number of Participants Analyzed\" contributed data to the table but may not have data evaluable for each row.","reportingStatus":"POSTED","timeFrame":"From date of randomization until documented PD, or start of subsequent anticancer therapy or death, whichever occurred first (maximum up to 33.9 months)","title":"SLI: ORR as Assessed by Investigator According to Line of Therapy - FAS","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}